2024 Q4 Form 10-Q Financial Statement

#000095017024126366 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3 2023 Q3
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.269M
YoY Change 37.43%
% of Gross Profit
Research & Development $29.19M $32.76M
YoY Change -10.89% 53.55%
% of Gross Profit
Depreciation & Amortization $558.0K $1.245M
YoY Change -55.18% 83.9%
% of Gross Profit
Operating Expenses $38.77M $41.03M
YoY Change -5.51% 50.0%
Operating Profit -$38.77M -$16.28M
YoY Change 138.12%
Interest Expense $1.353M
YoY Change 454.51%
% of Operating Profit
Other Income/Expense, Net $4.278M -$23.00K
YoY Change -18700.0% -28.13%
Pretax Income -$39.70M
YoY Change 94.63%
Income Tax
% Of Pretax Income
Net Earnings -$34.49M -$39.70M
YoY Change -13.12% 94.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80 -$23.27
Diluted Earnings Per Share -$0.80 -$0.97
COMMON SHARES
Basic Shares Outstanding 43.17M 43.15M 664.7K
Diluted Shares Outstanding 43.16M 664.7K

Balance Sheet

Concept 2024 Q4 2024 Q3 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $321.6M $77.27M
YoY Change 316.16%
Cash & Equivalents $104.7M $22.97M
Short-Term Investments $216.9M $54.31M
Other Short-Term Assets $3.787M $2.136M
YoY Change 77.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $325.4M $79.41M
YoY Change 309.74%
LONG-TERM ASSETS
Property, Plant & Equipment $3.151M $11.07M
YoY Change -71.54%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.876M $2.005M
YoY Change -6.43%
Total Long-Term Assets $13.82M $13.08M
YoY Change 5.71%
TOTAL ASSETS
Total Short-Term Assets $325.4M $79.41M
Total Long-Term Assets $13.82M $13.08M
Total Assets $339.2M $92.49M
YoY Change 266.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $9.932M $3.022M
YoY Change 228.66%
Accrued Expenses $13.69M $10.00M
YoY Change 36.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $931.0K $897.0K
YoY Change 3.79%
Total Short-Term Liabilities $30.99M $16.87M
YoY Change 83.63%
LONG-TERM LIABILITIES
Long-Term Debt $237.0K $1.078M
YoY Change -78.01%
Other Long-Term Liabilities $296.0K $5.766M
YoY Change -94.87%
Total Long-Term Liabilities $296.0K $6.844M
YoY Change -95.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.99M $16.87M
Total Long-Term Liabilities $296.0K $6.844M
Total Liabilities $36.49M $23.72M
YoY Change 53.83%
SHAREHOLDERS EQUITY
Retained Earnings -$226.0M
YoY Change
Common Stock $528.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $302.7M $68.77M
YoY Change
Total Liabilities & Shareholders Equity $339.2M $92.49M
YoY Change 266.75%

Cashflow Statement

Concept 2024 Q4 2024 Q3 2023 Q3
OPERATING ACTIVITIES
Net Income -$34.49M -$39.70M
YoY Change -13.12% 94.63%
Depreciation, Depletion And Amortization $558.0K $1.245M
YoY Change -55.18% 83.9%
Cash From Operating Activities -$27.49M -$33.85M
YoY Change -18.78% 24.0%
INVESTING ACTIVITIES
Capital Expenditures $102.0K $287.0K
YoY Change -64.46% -62.04%
Acquisitions
YoY Change
Other Investing Activities $778.0K -$40.18M
YoY Change -101.94% 41.04%
Cash From Investing Activities $676.0K -$40.47M
YoY Change -101.67% 38.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $60.27M
YoY Change 398.68%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -152.0K 59.55M
YoY Change -100.26% 397.01%
NET CHANGE
Cash From Operating Activities -27.49M -33.85M
Cash From Investing Activities 676.0K -40.47M
Cash From Financing Activities -152.0K 59.55M
Net Change In Cash -26.97M -14.76M
YoY Change 82.68% -66.87%
FREE CASH FLOW
Cash From Operating Activities -$27.49M -$33.85M
Capital Expenditures $102.0K $287.0K
Free Cash Flow -$27.59M -$34.13M
YoY Change -19.17% 21.68%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001994702
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.219
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.219
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41947
dei Entity Registrant Name
EntityRegistrantName
Kyverna Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1365411
dei Entity Address Address Line1
EntityAddressAddressLine1
5980 Horton St.
dei Entity Address Address Line2
EntityAddressAddressLine2
STE 550
dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
dei City Area Code
CityAreaCode
(510)
dei Local Phone Number
LocalPhoneNumber
925-2492
dei Security12b Title
Security12bTitle
Common Stock, par value $0.00001 per share
dei Trading Symbol
TradingSymbol
KYTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43171612
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104663000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34647000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
216924000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
22896000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3787000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3121000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
325374000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
60664000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
564000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
565000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3151000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2326000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7153000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6494000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1078000
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1790000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1876000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3356000
CY2024Q3 us-gaap Assets
Assets
339196000
CY2023Q4 us-gaap Assets
Assets
75195000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
9932000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4358000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4440000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2812000
CY2024Q3 kytx Accrued License Expense Related Party
AccruedLicenseExpenseRelatedParty
6250000
CY2023Q4 kytx Accrued License Expense Related Party
AccruedLicenseExpenseRelatedParty
6250000
CY2024Q3 kytx Other Accrued Expenses And Current Liabilities
OtherAccruedExpensesAndCurrentLiabilities
6432000
CY2023Q4 kytx Other Accrued Expenses And Current Liabilities
OtherAccruedExpensesAndCurrentLiabilities
3519000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3000000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1964000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
931000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
956000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
30985000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19859000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4968000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5238000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
237000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
921000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
296000
CY2024Q3 us-gaap Liabilities
Liabilities
36486000
CY2023Q4 us-gaap Liabilities
Liabilities
26018000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
490000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
140492016
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43167337
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43167337
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1250103
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1250103
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
528588000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4642000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
153000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226031000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136043000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
302710000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-131397000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339196000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75195000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29193000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13644000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78990000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32760000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9577000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2638000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22573000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8269000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
38770000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
16282000
us-gaap Operating Expenses
OperatingExpenses
101563000
us-gaap Operating Expenses
OperatingExpenses
41029000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38770000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-16282000
us-gaap Operating Income Loss
OperatingIncomeLoss
-101563000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41029000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4355000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
880000
us-gaap Investment Income Interest
InvestmentIncomeInterest
11784000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1493000
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
32000
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
50000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
115000
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
140000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-94000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4278000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
817000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
11575000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1330000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-34492000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15465000
us-gaap Net Income Loss
NetIncomeLoss
-89988000
us-gaap Net Income Loss
NetIncomeLoss
-39699000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
190000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
149000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
31000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
190000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
5000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
149000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
31000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34302000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-15460000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-89839000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39668000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-62.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-62.75
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43155858
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43155858
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
664656
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
664656
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36702183
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36702183
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
632624
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
632624
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-131397000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
30686000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
336164000
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
180574000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
64000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2278000
CY2024Q1 kytx Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
6000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26693000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
360991000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
73000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1284000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-28803000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-36000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
333509000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
90000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3413000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-34492000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
190000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
302710000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-73997000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
24000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
468000
CY2023Q1 kytx Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
18000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11143000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
18000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-84612000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
51000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
36000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
447000
CY2023Q2 kytx Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
17000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13091000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
8000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-97195000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
49000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
310000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
521000
CY2023Q3 kytx Vesting Of Early Exercised Options And Restricted Stock
VestingOfEarlyExercisedOptionsAndRestrictedStock
18000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15465000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-111806000
us-gaap Net Income Loss
NetIncomeLoss
-89988000
us-gaap Net Income Loss
NetIncomeLoss
-39699000
us-gaap Share Based Compensation
ShareBasedCompensation
6975000
us-gaap Share Based Compensation
ShareBasedCompensation
1436000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5428000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
510000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1570000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1245000
kytx Non Cash Lease Expense
NonCashLeaseExpense
1859000
kytx Non Cash Lease Expense
NonCashLeaseExpense
1266000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
666000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
207000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
995000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
37000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6034000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1104000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1628000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
444000
kytx Increase Decrease In Other Accrued Expenses And Current Liabilities
IncreaseDecreaseInOtherAccruedExpensesAndCurrentLiabilities
3278000
kytx Increase Decrease In Other Accrued Expenses And Current Liabilities
IncreaseDecreaseInOtherAccruedExpensesAndCurrentLiabilities
2327000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
296000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1752000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1216000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-77189000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33847000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
362751000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
53862000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
174300000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13683000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1673000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
287000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-190124000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-40466000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
341171000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
59900000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
227000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
370000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
709000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
562000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3361000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
156000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
337328000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59552000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70015000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14761000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
35212000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38289000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105227000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23528000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104663000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22967000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
564000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
561000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
105227000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23528000
kytx Conversion Of Redeemable Convertible Preferred Stock Into Common Stock On Completion Of Initial Public Offering Shares
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockOnCompletionOfInitialPublicOfferingShares
114556997
kytx Conversion Of Redeemable Convertible Preferred Stock Into Common Stock On Completion Of Initial Public Offering Amount Converted
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockOnCompletionOfInitialPublicOfferingAmountConverted
180574000
kytx Unpaid Deferred Offering Costs Included In Accounts Payable And Other Current Liabilities
UnpaidDeferredOfferingCostsIncludedInAccountsPayableAndOtherCurrentLiabilities
729000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
kytx Non Cash Vesting Of Restricted Stock
NonCashVestingOfRestrictedStock
6000
kytx Non Cash Vesting Of Restricted Stock
NonCashVestingOfRestrictedStock
53000
kytx Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
2518000
kytx Right Of Use Asset Obtained In Exchange For Operating And Finance Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingAndFinanceLeaseLiability
854000
us-gaap Interest Paid Net
InterestPaidNet
115000
us-gaap Interest Paid Net
InterestPaidNet
140000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-06-14
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
On January 30, 2024, the Company’s shareholders approved and the Company effected a reverse stock split of the shares of common stock at a ratio of 1-for-4.5511 (the “Reverse Stock Split”). The number of authorized shares and par value per share were not adjusted as a result of the Reverse Stock Split. All references to shares, restricted stock awards, restricted stock units and options to purchase common stock, share data, per share data, and related information contained in the financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. The conversion ratios for each series of the Company’s redeemable convertible preferred stock, which was automatically converted into shares of common stock upon the closing of the IPO, were proportionally adjusted.
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-226000000
us-gaap Net Income Loss
NetIncomeLoss
-90000000
us-gaap Net Income Loss
NetIncomeLoss
-39700000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
321600000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accrued expenses, valuation of its common stock prior to the IPO, stock-based compensation, valuation of deferred tax assets and uncertain income tax positions. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the amount reported as revenue and expenses that are not readily apparent from other sources. Actual results may differ materially from those estimates.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
318883000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
154000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
319036000
CY2024Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
102100000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
216900000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22892000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22896000
CY2024Q3 kytx Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
kytx Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
CY2023Q3 kytx Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
kytx Impairment Loss On Debt Securities Available For Sale
ImpairmentLossOnDebtSecuritiesAvailableForSale
0
CY2024Q3 us-gaap Interest Receivable Noncurrent
InterestReceivableNoncurrent
300000
CY2023Q4 us-gaap Interest Receivable Noncurrent
InterestReceivableNoncurrent
0
CY2024Q3 us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0
us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6497000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4814000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3346000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2488000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3151000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2326000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
kytx Milestone Payments Achieved Or Probable
MilestonePaymentsAchievedOrProbable
0
CY2023 kytx Milestone Payments Achieved Or Probable
MilestonePaymentsAchievedOrProbable
0
CY2024Q3 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
0
CY2023Q4 us-gaap Royalty Guarantees Commitments Amount
RoyaltyGuaranteesCommitmentsAmount
0
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
As of September 30, 2024, the Company leased 68,153 square feet of office and laboratory space in Emeryville, California under operating leases which have terms through February 2027.
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
854000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
602000
us-gaap Operating Lease Cost
OperatingLeaseCost
2398000
us-gaap Operating Lease Cost
OperatingLeaseCost
1821000
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
237000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
216000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
712000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
607000
CY2024Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
33000
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
49000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
115000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
140000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
1000
CY2024Q3 us-gaap Variable Lease Cost
VariableLeaseCost
262000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
246000
us-gaap Variable Lease Cost
VariableLeaseCost
814000
us-gaap Variable Lease Cost
VariableLeaseCost
730000
CY2024Q3 us-gaap Lease Cost
LeaseCost
1386000
CY2023Q3 us-gaap Lease Cost
LeaseCost
1113000
us-gaap Lease Cost
LeaseCost
4039000
us-gaap Lease Cost
LeaseCost
3299000
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
811000
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
602000
us-gaap Operating Lease Payments
OperatingLeasePayments
2245000
us-gaap Operating Lease Payments
OperatingLeasePayments
1769000
CY2024Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
33000
CY2023Q3 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
49000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
115000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
140000
CY2024Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
241000
CY2023Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
206000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
709000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
562000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2518000
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
110000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
854000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
816000
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
274000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3563000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
887000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4046000
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
179000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
446000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8871000
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1340000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
903000
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
172000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7968000
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1168000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3000000
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
931000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4968000
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
237000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.11
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.08
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.11
CY2024Q1 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
25171265
CY2024Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2024Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12407880
CY2023Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29619628
CY2022Q4 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
349321
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
1100000
CY2022Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0427
CY2022Q4 kytx Debt Instrument Maturity Month Year
DebtInstrumentMaturityMonthYear
2027-12
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4310034
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.09
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M2D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11810000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3539804
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.29
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
420290
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
312739
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
4031
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
4.42
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7112778
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2854000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1851204
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.55
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M4D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2486000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
7112778
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y6M7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2854000
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
349321
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
885937
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.43
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.01
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3500000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2024Q3 kytx Repurchase Liability Related To Unvested Shares
RepurchaseLiabilityRelatedToUnvestedShares
0
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0
CY2023 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
8125
CY2023 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
349321
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3413000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
521000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6975000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1436000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-34492000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-15465000
us-gaap Net Income Loss
NetIncomeLoss
-89988000
us-gaap Net Income Loss
NetIncomeLoss
-39699000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
43155858
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
43155858
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
664656
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
664656
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
36702183
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
36702183
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
632624
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
632624
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.8
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.8
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-23.27
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-23.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-62.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-62.75
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7657629
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27891642
CY2024Q3 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0

Files In Submission

Name View Source Status
0000950170-24-126366-index-headers.html Edgar Link pending
0000950170-24-126366-index.html Edgar Link pending
0000950170-24-126366.txt Edgar Link pending
0000950170-24-126366-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kytx-20240930.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kytx-20240930.xsd Edgar Link pending
kytx-ex31_1.htm Edgar Link pending
kytx-ex31_2.htm Edgar Link pending
kytx-ex32_1.htm Edgar Link pending
kytx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
kytx-20240930_htm.xml Edgar Link completed